Hershberg Robert
SEC-identified person · CIK 1274139 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Recursion Pharmaceuticals, INC. RXRX | Director | filed 2021 - 2026 |
| Ataibeckley Inc. ATAI | Director | filed 2026 - 2026 |
| Adaptive Biotechnologies Corp ADPT | Director | filed 2019 - 2026 |
| Atai Beckley N.V. ATAI | Director | filed 2025 - 2025 |
| Hillevax, Inc. HLVX | Director · See Remarks | filed 2022 - 2025 |
| Fate Therapeutics INC fate | Director | filed 2020 - 2023 |
| Silverback Therapeutics, Inc. SPRY | Director | filed 2020 - 2022 |
| Nanostring Technologies Inc NSTG | Director | filed 2015 - 2022 |
| Dendreon Corp DNDNQ | Sr. VP & Chief Medical Officer | filed 2006 - 2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.